Triple-negative breast cancer trials in Belgium
16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Where
- Gent, Sint-Lambrechts-Woluwe, Yvoir
- Age
- 18 years and over
- People
- 1,530 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00 - Phase 3Taking peopleStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Where
- Anderlecht, Antwerp, Brasschaat, Brussels, Charleroi, Hasselt, Leuven, Liège, Roeselare, Sint-Niklaas
- Age
- 18 years and over
- People
- 1,514 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00 - Phase 3Taking peopleROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Where
- Bonheiden, Charleroi, Jette, Leuven, Liège, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 558 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00 - Phase 2Taking peopleHER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
- Where
- Aalst, Anderlecht, Brussels, Jette, Leuven, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Abscint NV/SA
See details and how to joinNCT06369831 · EU 2024-511419-22-00 - Phase 1Not yet taking people in BelgiumA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00 - Phase 3Taking peopleA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Where
- Antwerp, Genk, Ghent
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00 - Phase 3Taking peopleA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Where
- Aalst, Gent, Hasselt, Liège, Namur
- Age
- 18 years and over
- People
- 2,400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00 - Phase 1/2Taking peopleStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- Where
- Antwerp, Brussels, Liège
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT05985655 - Phase 1/2Taking peopleA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- Where
- Anderlecht, Leuven
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00 - Phase 2Taking peopleLifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer
- Where
- Antwerp, Brussels, Ghent, Hasselt, Kortrijk, Leuven, Liège, Namur
- Age
- 18 years and over
- People
- 356
- Run by
- Universitaire Ziekenhuizen KU Leuven
See details and how to joinNCT06831955 - Phase 1Taking peoplePhase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Where
- Brussels
- Age
- 18 years to 100 years
- People
- 162 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06562192 - Phase 3Taking peoplePersonalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
- Where
- Anderlecht, Antwerp, Brussels, Charleroi, Gent, Jette, La Louvière, Leuven, Liège, Lobbes, Namur, Nivelles, Sint-Lambrechts-Woluwe
- Age
- 18 years and over
- People
- 2,454 worldwide
- Run by
- UNICANCER
See details and how to joinNCT06606730 · EU 2024-515787-31-00 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Anderlecht
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - Phase 2Taking peopleBicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
- Where
- Antwerp, Edegem, Gent, Hasselt, Jette, Leuven
- Age
- 18 years and over
- People
- 53
- Run by
- Universitaire Ziekenhuizen KU Leuven
See details and how to joinNCT06365788 · EU 2022-502272-23-00 - Phase 1/2Taking peoplePhase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
- Where
- Brussels, Ghent
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- Maastricht University Medical Center
See details and how to joinNCT04954599 - Phase 2Taking peoplePSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.
- Where
- Brussels
- Age
- 18 years and over
- People
- 20
- Run by
- Jules Bordet Institute
See details and how to joinNCT06059469